Start with the case.
Create a case, add the sample details, and upload variants. Keep the genome build, assay, and biomarkers together from the start.
Case → variants → annotation
MOLECULAR FINDINGS. MEANINGFUL CONTEXT.
From variants
to a clearer
picture.
Connect molecular findings with therapy evidence. Review every association in context, then bring your reasoning together in a traceable report.
Research use only. Pilot onboarding is reviewed manually.
ONE CASE. EVERY STEP CONNECTED.
DM-2026-008
Non-small cell lung cancer
Variants added4 findings · GRCh38 · targeted DNA panel
Accepted
Evidence in contextSource, direction, and review decision
REVIEW
Resistance stays visibleReviewed alongside sensitivity evidence
REVIEWED FINDINGSVERSIONED REPORT
A report with the reasoning intactFindings · evidence · provenance · limitations
A case-centered workspace
Human review at each step
Evidence with its provenance
Research-use safeguards
A WORKFLOW YOU CAN FOLLOW
Less searching.
More understanding.
Move from an uploaded file to a reviewed report in one workspace. Your case context and review decisions travel with you.
Review with context.
See the alteration, therapy association, evidence direction, and source together. Record what belongs in the report and what does not.
Findings → evidence → your decision
Make the reasoning clear.
Create a report snapshot from your review. Keep resistance cautions, source records, and limitations visible alongside the findings.
Review → versioned report → sharing
THE FINDING IS ONLY THE BEGINNING
Evidence means more
with its context intact.
Drugmarker keeps the path from a molecular finding to its supporting record visible, so the review can be understood beyond a single result.
Every association has a direction.
Sensitivity and resistance are distinct, visible signals.
Every decision has a record.
Included, excluded, and pending findings remain distinguishable.
Every report has a version.
A report captures a review snapshot; later changes are flagged.
Drugmarker
EXAMPLE REPORT
Molecular evidence report
DM-2026-008 · Non-small cell lung cancer
EGFR · L858RIncluded findingAccepted
EGFR · T790MResistance contextResistance
TP53 · R273HIncluded findingAccepted
Research use onlyVersioned snapshot
BEFORE YOU GET STARTED
A few useful answers.
Who is Drugmarker designed for?
Researchers and clinical teams working with molecular findings and therapy evidence. The workspace is organized around case review, interpretation, and reporting.
How do I join a research workspace?
Request access with your role and organization. The flow is request review, an invitation, then account setup.
Is the example report clinical guidance?
No. Its case and review decisions are illustrative. Evidence associations do not represent current prescribing guidance or a treatment recommendation.
What is connected?
VEP, ClinVar, CIViC, ClinicalTrials.gov, report generation, audit, and email are connected to the research platform. OncoKB is enabled when a licensed token is available.
A clearer workspace for your next case.
Request access for your research team, or sign in to continue a review.